Understanding Chronic Migraines

Prevalence and Impact

Chronic migraines are defined as headaches occurring for 15 or more days each month for a duration of over three months. This condition affects approximately 1-2% of the global population, leading to a significant decline in quality of life. Individuals suffering from chronic migraines often experience various co-morbidities.

Current Treatment Options

Several medications are available for managing chronic migraines, including topiramate, beta-blockers, and amitriptyline. However, these treatments often exhibit limited efficacy and poor tolerability, resulting in low adherence rates among patients. This scenario emphasizes the need for more effective and safer alternatives.

Novel Target in Migraine Treatment

Calcitonin Gene-Related Peptide (CGRP)

Research has identified Calcitonin gene-related peptide (CGRP) as a critical target in the pathophysiology of migraines. Small-molecule treatments, known as gepants, have shown effectiveness in acute migraine management. Nevertheless, gepants have been linked to liver toxicity, leading to the cessation of their development. Consequently, the focus has shifted to erenumab, an antibody designed to target the CGRP receptor.

Recent Research Findings

Efficacy and Safety Study

A recent randomized, double-blind, placebo-controlled study published in The Lancet Neurology evaluated the efficacy and safety of erenumab for chronic migraine treatment. The study involved 667 participants aged 18 to 65 with chronic migraines, who were randomly assigned to one of three groups: a placebo group (n=286), a 70-mg erenumab group (n=191), or a 140-mg erenumab group (n=190). Erenumab was administered via subcutaneous injection every four weeks over a total period of 12 weeks.

Results and Observations

The findings indicated that erenumab significantly reduced the number of migraine days per month compared to the placebo group during the last four weeks of the study. Notably, the efficacy of erenumab was evident within the first four weeks, highlighting the drug’s rapid action. Both dosages of erenumab demonstrated effectiveness in alleviating the migraine burden, and there was no significant difference in adverse events between the placebo and erenumab groups, suggesting good tolerability.

Conclusion and Future Directions

The study concludes that subcutaneous injections of 70 and 140 mg of erenumab every four weeks represent effective and safe treatment options for chronic migraines. Additionally, five other independent studies have corroborated the efficacy and safety of CGRP-targeting antibodies, underscoring the vital role of CGRP in migraine pathophysiology. Further research is essential to elucidate the precise role of CGRP in chronic migraines and to evaluate the long-term effects of erenumab.

Written By: Haisam Shah, BSc